Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 10, 2013, Pages 6135-6140

  Chen, Si Ying ^a   Hu, Sa Sa ^a   Dong, Qian ^b   Cai, Jiang Xia ^a   Zhang, Wei Peng ^a   Sun, Jin Yao ^a   Wang, Tao Tao ^a   Xie, Jiao ^a   He, Hai Rong ^a   Xing, Jian Feng ^a   Lu, Jun ^a   Dong, Ya Lin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Qilu Institute of Pharmaceutical Research   (China)

Author keywords

Breast cancer; Chemotherapy; Multidrug resistance; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CULTURE TECHNIQUE; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IN VITRO STUDY; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 84890479612     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.10.6135     Document Type: Article

References (28)

1. Arai T, Miyoshi Y, Kim S J, et al (2008). Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol, 34, 734-8.
2. Arteaga CL, Moulder SL, Yakes FM (2002). HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol, 29, 4-10.
3. Baguley BC (2010). Multiple Drug Resistance Mechanisms in Cancer. Mol Biotechnol, 46, 308-16.
4. Ballerini S, Bellincampi L, Bernardini S, et al (2003). Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction. Clinica Chimica Acta, 329, 127-32.
5. Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010). Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol, 7, 22-36.
6. Bhoo-Pathy N, Yip CH, Hartman M, et al (2013). Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer, 49, 703-9.
7. Coughlin SS, Ekwueme DU (2009). Breast cancer as a global health concern. Cancer Epidemiol, 33, 315-8.
8. Dizdarevic S, Peters AM (2011). Imaging of multidrug resistance in cancer. Cancer Imaging, 11, 1-8.
9. Fromm MF (2002). The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev, 54, 1295-310.
10. Gu W, Fang FF, Li B, Cheng BB, Ling CQ (2012).Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. Asian Pac J Cancer Prev, 13, 4807-14.
11. Kaira K, Takahashi T, Murakami H, et al (2013). The role of betaIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol, 18, 371-9.
12. Kerr EH, Frederick PJ, Egger ME, et al (2013). Lung resistancerelated protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Ann Surg Oncol, 20, 3059-65.
13. Lloyd HH (1974). Combination chemotherapy: considerations for design and analysis. Cancer Chemother Rep 2, 4, 157-65.
14. Lu L, Zhou D, Jiang X, et al (2012). Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/Adr: possible implication in the enhanced invasive ability. Eur Rev Med Pharmacol Sci, 16, 1271-9.
15. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C (2012). Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev, 38, 890-903.
16. Podolski-Renić A, Andelkovic T, Bankovic J, et al (2011). The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed Pharmacother, 65, 345-53.
17. Saeki T, Tsuruo T, Sato W, Nishikawsa K (2005). Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol, 56, 84-9.
18. Saloustros E, Mavroudis D, Georgoulias V (2008). Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother, 9, 2603-16.
19. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41.
20. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92.
21. Smoter M, Bodnar L, Duchnowska R, et al (2011). The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol, 68, 553-7.
22. Snow K, Judd W (1991). Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. Br J Cancer, 63, 17-28.
23. Song YN, Guo XL, Zheng BB, et al (2011). Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTpi activity. Toxicology In Vitro, 25, 937-43.
24. Urruticoechea A, Smith IE, Dowsett M (2005). Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 23, 7212-20.
25. Yu ST, Chen TM, Chern JW, Tseng SY, Chen YH (2009). Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis. Anticancer Drugs, 20, 382-8.
26. Zhang W, Ding W, Chen Y, et al (2011). Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai), 43, 647-53.
27. Zhao YX, Liang WQ, Wang Y, Liu DX (2011). Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells. Pharmazie, 66, 130-5.
28. Zhou HL, Zheng YJ, Cheng XZ, et al (2013). Intercellular transfer of P-glycoprotein from the drug resistant human bladder cancer cell line BIU-87 does not require cell-to-cell contact. J Urol, 190, 1069-75.